Abstract
In the future, it is advisable to expand the understanding of the role of biomarkers
in the diagnosis and dynamic monitoring of profile patients, to determine the optimal duration of
treatment and possible timing of the resumption of menopausal hormone therapy after an episode
of GE. It is also necessary to assess the impact of weight loss, including after bariatric surgery,
and lifestyle changes on the frequency of relapses of the disease and the possibility of regression
of hyperplasia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2023 Khasanova M. T.